Drug intelligence / Profile preview

betiatide

Development stage
Approved
Lead developer
Jubilant DraxImage
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

Betiatide is a small molecule oligopeptide used as the active pharmaceutical ingredient in kits for the preparation of technetium Tc 99m mertiatide, a radiopharmaceutical diagnostic agent. After reconstitution with sodium pertechnetate Tc 99m, it forms technetium Tc 99m mertiatide, which is administered intravenously to assess renal function. The mechanism of action involves rapid uptake by renal tubular cells and excretion via urine through both tubular secretion and glomerular filtration. This allows for gamma camera imaging to evaluate kidney perfusion, function, split function, angiograms, and renogram curves for both whole kidney and cortex. Betiatide is primarily indicated for diagnosing congenital or acquired renal abnormalities, urinary tract obstruction or calculi (stones), and assessing renal failure[2][5][6][7][8].

Brand names
TechneScan MAG3
Other names
betiatidaS-benzoylmercaptoacetyltriglycine
02

Targets

OAT1 (Organic anion transporter 1)SLC22A8 (Organic anion transporter 3)

Beyond the preview

Go deeper on betiatide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on betiatide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call